v3.26.1
Share-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2026
Share-Based Payment Arrangement [Abstract]  
Summary of Stock-Based Compensation Expense

The following table sets forth the total stock-based compensation expense related to stock options and restricted stock units included in the respective components of operating expenses in the condensed consolidated income statements:

 

 

 

Three Months Ended March 31,

 

 

 

2026

 

 

2025

 

(in thousands)

 

Unaudited

 

 

Unaudited

 

Research and development

 

$

424

 

 

$

684

 

Clinical operations

 

 

126

 

 

 

93

 

Sales and marketing

 

 

657

 

 

 

451

 

General and administrative

 

 

1,752

 

 

 

1,105

 

Total stock-based compensation expense

 

$

2,959

 

 

$

2,333